Novartis FY2026 Earnings Forecast Raised by Erste Group Bank

Key Points

• Erste Group Bank raised Novartis’ FY2026 EPS forecast to $9.24 from $9.14, above the analyst consensus of $8.89.
• Analyst sentiment remains mixed: Novartis has a consensus “Hold” rating from 20 analysts, with a $145.60 average price target.
• Novartis shares opened at $143.85, while the company’s latest quarterly results included $2.41 EPS and $14.95 billion in revenue; institutional investors own 13.12% of the stock.

Novartis AG (NYSE:NVS - Free Report) - Equities research analysts at Erste Group Bank lifted their FY2026 earnings per share (EPS) estimates for shares of Novartis in a research note issued to investors on Thursday, October 8th. Erste Group Bank analyst H. Engel now expects that the company will earn $9.24 per share for the year, up from their previous forecast of $9.14. The consensus estimate for Novartis' current full-year earnings is $8.89 per share.

Other equities analysts have also issued research reports about the stock. HSBC upgraded shares of Novartis from a "reduce" rating to a "hold" rating and increased their price objective for the company from $123.00 to $136.00 in a research report on Thursday, September 10th. Morgan Stanley restated an "overweight" rating and set a $156.00 target price on shares of Novartis in a research report on Tuesday, October 6th. Royal Bank Of Canada began coverage on shares of Novartis in a research report on Tuesday, September 8th. They set a "sector perform" rating on the stock. Citigroup reaffirmed a "buy" rating on shares of Novartis in a report on Wednesday, July 22nd. Finally, JPMorgan Chase & Co. reiterated a "buy" rating on shares of Novartis in a research report on Sunday, August 9th. Six research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $145.60.

Novartis Trading Up 0.1%

Shares of NVS opened at $143.85 on Tuesday. The stock has a market capitalization of $274.49 billion, a PE ratio of 21.70, a P/E/G ratio of 2.74 and a beta of 0.41. The company's fifty day moving average is $148.91 and its 200 day moving average is $150.53. The company has a debt-to-equity ratio of 0.89, a quick ratio of 0.67 and a current ratio of 0.86. Novartis has a fifty-two week low of $121.57 and a fifty-two week high of $170.46.

Novartis (NYSE:NVS - Get Free Report) last posted its earnings results on Tuesday, June 30th. The company reported $2.41 EPS for the quarter. Novartis had a return on equity of 38.56% and a net margin of 23.29%. The firm had revenue of $14.95 billion during the quarter.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Woodstock Corp grew its stake in Novartis by 21.4% during the 3rd quarter. Woodstock Corp now owns 3,407 shares of the company's stock worth $486,000 after buying an additional 600 shares during the last quarter. JGP Wealth Management LLC raised its position in Novartis by 13.4% during the third quarter. JGP Wealth Management LLC now owns 2,847 shares of the company's stock valued at $406,000 after acquiring an additional 336 shares in the last quarter. HF Advisory Group LLC lifted its holdings in Novartis by 4.0% in the third quarter. HF Advisory Group LLC now owns 8,897 shares of the company's stock valued at $1,268,000 after acquiring an additional 346 shares during the period. GK Wealth Management LLC acquired a new position in Novartis in the third quarter valued at approximately $146,000. Finally, Wedmont Private Capital boosted its position in Novartis by 50.8% in the 3rd quarter. Wedmont Private Capital now owns 8,890 shares of the company's stock worth $1,272,000 after purchasing an additional 2,996 shares in the last quarter. Hedge funds and other institutional investors own 13.12% of the company's stock.

About Novartis

Novartis AG is a Switzerland-based pharmaceutical company focused on the discovery, development and commercialization of innovative medicines. The company's research and commercial activities center on cardiovascular, renal and metabolic diseases, immunology, neuroscience, oncology and hematology. Its portfolio includes prescription medicines such as Entresto, Cosentyx, Kesimpta, Kisqali, Pluvicto, Leqvio and Jakavi, as well as other therapies for serious and chronic conditions.

Novartis serves patients and healthcare providers in markets worldwide, with operations spanning North America, Europe, Asia and other international regions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.